Abstract
Non-small cell lung cancer (NSCLC) accounts for more deaths than any other cancer. Treatments are limited, and prognoses are usually very poor. Amitripyline is a tricyclic antidepressant with multiple effects which may give a variety of benefits to lung cancer patients. Effects on pain, mood, and sleep are of clear potential benefit and are well established, whereas effects on cough and respiratory function are currently under investigation. In addition, potential antitumour effects have yet to be comprehensively tested. Beneficial effects are limited by dose dependent toxicity and adverse effects. Nevertheless, amitriptyline appears to have place in the management of lung cancer and warrants further investigation.
Keywords: Amitriptyline, lung cancer, non-small cell lung cancer, NSCLC.
Current Cancer Therapy Reviews
Title:The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Volume: 10 Issue: 3
Author(s): John C. Ashton
Affiliation:
Keywords: Amitriptyline, lung cancer, non-small cell lung cancer, NSCLC.
Abstract: Non-small cell lung cancer (NSCLC) accounts for more deaths than any other cancer. Treatments are limited, and prognoses are usually very poor. Amitripyline is a tricyclic antidepressant with multiple effects which may give a variety of benefits to lung cancer patients. Effects on pain, mood, and sleep are of clear potential benefit and are well established, whereas effects on cough and respiratory function are currently under investigation. In addition, potential antitumour effects have yet to be comprehensively tested. Beneficial effects are limited by dose dependent toxicity and adverse effects. Nevertheless, amitriptyline appears to have place in the management of lung cancer and warrants further investigation.
Export Options
About this article
Cite this article as:
C. Ashton John, The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer, Current Cancer Therapy Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/157339471003150212112220
DOI https://dx.doi.org/10.2174/157339471003150212112220 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties
Anti-Cancer Agents in Medicinal Chemistry STAT Signaling and Cell Function
Current Genomics <i>In Silico</i> Docking Studies of Vascular Endothelial Growth Factor-A (VEGFA): Possible Implications in Chronic Myeloid Leukemia (CML) Therapy
Current Proteomics Evaluation of Oxidative Stress Biomarkers in Brain Metastatic and Non-Metastatic Lung Cancer Patients with Different Cell Types
Anti-Cancer Agents in Medicinal Chemistry Oxidative Stress Based-Biomarkers in Oral Carcinogenesis: How Far Have We Gone?
Current Molecular Medicine Driving Neural Stem Cells Towards a Desired Phenotype
Current Stem Cell Research & Therapy Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science Plasmid-Mediated Muscle-Targeted Gene Therapy for Circulating Therapeutic Protein Replacement: A Tale of the Tortoise and the Hare?
Current Gene Therapy Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Ellipticine, its Derivatives: Re-evaluation of Clinical Suitability with the Aid of Drug Delivery Systems
Current Cancer Drug Targets Composite Lymphomas: A Challenging Entity
Current Cancer Therapy Reviews Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy Genetic and Environmental Influences on Therapeutic and Toxicity Outcomes: Studies with CYP2A6
Current Clinical Pharmacology Lung Cancer Brachytherapy
Current Cancer Therapy Reviews New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Changes of Expression of the Protein C Pathway Components in LPSInduced Endotoxemia–Implication for Sepsis
Cardiovascular & Hematological Disorders-Drug Targets Efficacy of Chemopreventive Agents in Mouse Mammary Gland Organ Culture (MMOC) Model: A Comprehensive Review
Current Medicinal Chemistry Recombinant Human IL-11 Promotes Lung Adenocarcinoma A549 Cell Growth and EMT through Activating STAT3/HIF-1α/EMT Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: ErbB Family and Downstream Signal Transduction Pathways as Targets for Anticancer Therapy (Guest Editor: F. Caponigro)]
Current Drug Targets